Potential of Heterogeneous Compounds As Antidepressants: A Narrative Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Nov 26

PMID 36430254

Authors

Gonghui Hu

Meng Zhang

Yuyang Wang

Ming Yu

Yu Zhou

Affiliations

Soon will be listed here.

Abstract

Depression is a globally widespread disorder caused by a complicated interplay of social, psychological, and biological factors. Approximately 280 million people are suffering from depression worldwide. Traditional frontline antidepressants targeting monoamine neurotransmitters show unsatisfactory effects. The development and application of novel antidepressants for dissimilar targets are on the agenda. This review characterizes the antidepressant effects of multiple endogenous compounds and/or their targets to provide new insight into the working mechanism of antidepressants. We also discuss perspectives and challenges for the generation of novel antidepressants.

References

Kennard L, Chumbley J, Ranatunga K, Armstrong S, Veale E, Mathie A . Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol. 2005; 144(6):821-9. PMC: 1576064. DOI: 10.1038/sj.bjp.0706068. View

Bauer M, Heinz A, Whybrow P . Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002; 7(2):140-56. DOI: 10.1038/sj.mp.4000963. View

Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky S, Anderson J, Jung S . The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci. 2008; 11(7):752-3. PMC: 2765052. DOI: 10.1038/nn.2139. View

Kranaster L, Hoyer C, Aksay S, Bumb J, Leweke F, Janke C . Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017; 267(8):781-786. DOI: 10.1007/s00406-017-0789-7. View

Keck M, Welt T, Muller M, Uhr M, Ohl F, Wigger A . Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology. 2003; 28(2):235-43. DOI: 10.1038/sj.npp.1300040. View

Serrenho D, Santos S, Carvalho A . The Role of Ghrelin in Regulating Synaptic Function and Plasticity of Feeding-Associated Circuits. Front Cell Neurosci. 2019; 13:205. PMC: 6546032. DOI: 10.3389/fncel.2019.00205. View

Venkatachalam K, Zhong S, Dubiel M, Satala G, Sadek B, Stark H . The Novel Pimavanserin Derivative ST-2300 with Histamine H Receptor Affinity Shows Reduced 5-HT Binding, but Maintains Antidepressant- and Anxiolytic-like Properties in Mice. Biomolecules. 2022; 12(5). PMC: 9138994. DOI: 10.3390/biom12050683. View

Martinowich K, Schloesser R, Lu Y, Jimenez D, Paredes D, Greene J . Roles of p75(NTR), long-term depression, and cholinergic transmission in anxiety and acute stress coping. Biol Psychiatry. 2011; 71(1):75-83. PMC: 3230751. DOI: 10.1016/j.biopsych.2011.08.014. View

Moreno S, Devader C, Pietri M, Borsotto M, Heurteaux C, Mazella J . Altered Trek-1 Function in Sortilin Deficient Mice Results in Decreased Depressive-Like Behavior. Front Pharmacol. 2018; 9:863. PMC: 6088259. DOI: 10.3389/fphar.2018.00863. View

10.

Lindholm J, Autio H, Vesa L, Antila H, Lindemann L, Hoener M . The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice. Neuropharmacology. 2011; 62(1):391-7. DOI: 10.1016/j.neuropharm.2011.08.015. View

11.

Medhurst A, Rennie G, Chapman C, Meadows H, Duckworth M, Kelsell R . Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery. Brain Res Mol Brain Res. 2001; 86(1-2):101-14. DOI: 10.1016/s0169-328x(00)00263-1. View

12.

Nykjaer A, Willnow T . Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012; 35(4):261-70. DOI: 10.1016/j.tins.2012.01.003. View

13.

Thul T, Corwin E, Carlson N, Brennan P, Young L . Oxytocin and postpartum depression: A systematic review. Psychoneuroendocrinology. 2020; 120:104793. PMC: 7526479. DOI: 10.1016/j.psyneuen.2020.104793. View

14.

Moha Ou Maati H, Veyssiere J, Labbal F, Coppola T, Gandin C, Widmann C . Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology. 2011; 62(1):278-88. DOI: 10.1016/j.neuropharm.2011.07.019. View

15.

Skibicka K, Hansson C, Egecioglu E, Dickson S . Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression. Addict Biol. 2011; 17(1):95-107. PMC: 3298643. DOI: 10.1111/j.1369-1600.2010.00294.x. View

16.

Bauer M, London E, Silverman D, Rasgon N, Kirchheiner J, Whybrow P . Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003; 36 Suppl 3:S215-21. DOI: 10.1055/s-2003-45133. View

17.

Emiliano A, Cruz T, Pannoni V, Fudge J . The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRIs therapeutic effects?. Neuropsychopharmacology. 2006; 32(5):977-88. DOI: 10.1038/sj.npp.1301206. View

18.

Realini N, Vigano D, Guidali C, Zamberletti E, Rubino T, Parolaro D . Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology. 2010; 60(2-3):235-43. DOI: 10.1016/j.neuropharm.2010.09.003. View

19.

Borsotto M, Veyssiere J, Moha Ou Maati H, Devader C, Mazella J, Heurteaux C . Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2014; 172(3):771-84. PMC: 4301688. DOI: 10.1111/bph.12953. View

20.

Milaneschi Y, Lamers F, Bot M, Drent M, Penninx B . Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. Biol Psychiatry. 2016; 81(9):807-814. DOI: 10.1016/j.biopsych.2015.10.023. View